Urogen Pharma (NASDAQ:URGN) Earns “Buy” Rating from HC Wainwright

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Wednesday, Marketbeat.com reports. They presently have a $45.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 69.56% from the company’s previous close.

A number of other equities analysts also recently issued reports on URGN. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 price objective for the company. D. Boral Capital reissued a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a report on Tuesday, March 31st. Finally, Oppenheimer restated an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Urogen Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.67.

Urogen Pharma Stock Down 1.8%

Shares of NASDAQ:URGN opened at $26.54 on Wednesday. Urogen Pharma has a fifty-two week low of $4.71 and a fifty-two week high of $32.37. The firm’s 50-day simple moving average is $23.91 and its 200-day simple moving average is $22.65. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -9.65 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million for the quarter, compared to analysts’ expectations of $44.83 million. On average, research analysts forecast that Urogen Pharma will post -0.98 EPS for the current year.

Institutional Trading of Urogen Pharma

Several large investors have recently modified their holdings of URGN. Osaic Holdings Inc. increased its stake in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Urogen Pharma by 27.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after buying an additional 486 shares in the last quarter. State of Wyoming acquired a new stake in Urogen Pharma during the 3rd quarter valued at $66,000. Russell Investments Group Ltd. grew its holdings in Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after buying an additional 3,125 shares during the last quarter. Finally, Strs Ohio purchased a new position in Urogen Pharma during the third quarter worth $76,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.